A practical reference on synaptogenesis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-14. Anything still debated is marked as such rather than presented as settled.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
=== Val66Met === A common SNP in the BDNF gene is rs6265. This point mutation in the coding sequence, a guanine to adenine switch at position 196, results in an amino acid switch: valine to methionine exchange at codon 66, Val66Met, which is in the prodomain of BDNF. Val66Met is unique to humans. The mutation interferes with normal translation and intracellular trafficking of BDNF mRNA, as it destabilizes the mRNA and renders it prone to degradation. The proteins resulting from mRNA that does get translated, are not trafficked and secreted normally, as the amino acid change occurs on the portion of the prodomain where sortilin binds; and sortilin is essential for normal trafficking. The Val66Met mutation results in a reduction of hippocampal tissue and has since been reported in a high number of individuals with learning and memory disorders, anxiety disorders, major depression, and neurodegenerative diseases such as Alzheimer's and Parkinson's. A meta-analysis indicates that the BDNF Val66Met variant is not associated with serum BDNF.
=== Preregistration === Orenetide (BP-101; BP101; Libicore; Desirix) – undefined mechanism of action (synthetic small peptide) – female sexual dysfunction [1] [2] Tadalafil oral film (AQST-119; Exordia) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [3] Tadalafil oral film (Exordia; INT-007; INT0007; INT0007/2006) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [4]
== Education and career == Turner holds a Bachelor of Medicine and Surgery (MBChB), a Diploma of Obstetrics Gynaecology and Family Planning (Dip Obs) and a Masters of Public Health (MPH Hons) from the University of Auckland. She was awarded a Diploma of Paediatrics (DHC) by the UK Royal College of Physicians. In 2014, the University of Auckland awarded Turner a Doctorate of Medicine (MD) for a thesis titled Factors associated with immunisation coverage for the childhood immunisation programme in New Zealand: 1999–2012. In 1997, in response to low immunisation coverage and equity gaps in the New Zealand immunisation programmes, Turner developed the Immunisation Advisory Centre, (IMAC) an organisation situated at the University of Auckland, that nationally provides independent and factual research-based scientific information regarding vaccine-preventable diseases and the benefits and risks of immunisation. Turner noted that at the time the Immunisation Advisory Centre was set up, there was a "vocal and influential anti-vaccination movement reflecting, an absence of trust in science and a primary healthcare system that wasn't very well organised...[but]...as the New Zealand community...got behind this, the angry anti-immunisation stuff [was] a lot less, because immunisation's normalised now as a positive part of raising healthy children. Whereas back then you had to make an active decision to immunise, now you have to make an active decision not to". As of 2023, Turner is Medical Directory for IMAC.
=== Crumpled graphene === In 2016, Brown University introduced a method for "crumpling" graphene, adding wrinkles to the material on a nanoscale. This was achieved by depositing layers of graphene oxide onto a shrink film, then shrunken, with the film dissolved before being shrunken again on another sheet of film. The crumpled graphene became superhydrophobic, and when used as a battery electrode, the material was shown to have as much as a 400% increase in electrochemical current density.
=== Flower and fruit === The flowers are monoecious, and open with or before the leaves. Once fully grown, these leaves are usually 3–6 millimetres (1⁄8–1⁄4 in) long on three-flowered clusters in the axils of the scales of drooping or erect catkins or aments. Staminate catkins are pendulous, clustered, or solitary in the axils of the last leaves of the branch of the year or near the ends of the short lateral branchlets of the year. They form in early autumn and remain rigid during the winter. The scales of the mature staminate catkins are broadly ovate, rounded, yellow or orange colour below the middle and dark chestnut brown at apex. Each scale bears two bractlets and three sterile flowers, each flower consisting of a sessile, membranous, usually two-lobed, calyx. Each calyx bears four short filaments with one-celled anthers or strictly, two filaments divided into two branches, each bearing a half-anther. Anther cells open longitudinally. The pistillate segments are erect or pendulous, and solitary, terminal on the two-leaved lateral spur-like branchlets of the year. The pistillate scales are oblong-ovate, three-lobed, pale yellow-green often tinged with red, becoming brown at maturity. These scales bear two or three fertile flowers, each flower consisting of a naked ovary. The ovary is compressed, two-celled, and crowned with two slender styles; the ovule is solitary. Each scale bears a single small, winged nut that is oval, with two persistent stigmas at the apex.
Sources: en.wikipedia.org
Because pellagra outbreaks occurred in regions where maize was a dominant food crop, the most convincing hypothesis during the late 19th century, as espoused by Cesare Lombroso, was that the maize either carried a toxic substance or was a carrier of disease. Louis Sambon, an Anglo-Italian doctor working at the London School of Tropical Medicine, was convinced that pellagra was carried by an insect, along the lines of malaria. Later, the lack of pellagra outbreaks in Mesoamerica, where maize is a major food crop, led researchers to investigate processing techniques in that region. Pellagra was studied mostly in Europe until the late 19th century, when it became epidemic especially in the Southern United States. In the early 1900s, pellagra reached epidemic proportions in the American South. Between 1906 and 1940 more than 3 million Americans were affected by pellagra with more than 100,000 deaths, yet the epidemic resolved itself right after dietary niacin fortification. Pellagra deaths in South Carolina numbered 1,306 during the first 10 months of 1915; 100,000 Southerners were affected in 1916. At this time, the scientific community held that pellagra was probably caused by a germ or some unknown toxin in corn.
=== Non-specific hydrophobic association === Amphitropic proteins associate with lipid bilayers via various hydrophobic anchor structures. Such as amphiphilic α-helixes, exposed nonpolar loops, post-translationally acylated or lipidated amino acid residues, or acyl chains of specifically bound regulatory lipids such as phosphatidylinositol phosphates. Hydrophobic interactions have been shown to be important even for highly cationic peptides and proteins, such as the polybasic domain of the MARCKS protein or histactophilin, when their natural hydrophobic anchors are present.
== Chemistry literature == Scientific literature Scientific journal Academic journal List of important publications in chemistry List of scientific journals in chemistry List of science magazines Scientific American
27 December – The Met Office issues a yellow weather warning for rain over Hogmanay, starting on 30 December and lasting over the New Year. Public Health Scotland says health services in Scotland are under "acute pressure" following a surge in flu cases. Caledonian MacBrayne is forced to reduce the number of passengers allowed on the MV Isle of Mull to 45 per journey after failing a safety check. 29 December – Emergency services searching for keen wild swimmer Ian Napier, missing from the Scousburgh Bay area since 27 December, find a body in the sea near Shetland. 30 December – Edinburgh's Hogmanay celebrations are cancelled amid weather warnings for heavy rain, high winds and snow over the New Year. 2025 New Year Honours: Among those to be recognised in the New Year Honours are broadcaster Jackie Bird (MBE), footballer and broadcaster Alan Hansen (MBE) and Olympic swimmer Duncan Scott (OBE).
=== Pharmacodynamics === Methylephedrine is a sympathomimetic and ephedrine-like agent. Ephedrine and related agents act as norepinephrine releasing agents and hence as indirectly acting sympathomimetics. In relation to this, methylephedrine stimulates α- and β-adrenergic receptors. The drug has bronchodilator and nasal decongestant effects. The occupancy of the dopamine transporter (DAT) by racemic methylephedrine has been studied.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.